Strongbridge Biopharma plc
|Market Cap (Intraday)||163.46M|
|2yr Forward PE||N/A|
Strongbridge Biopharma plc Stock, NASDAQ:SBBP
Strongbridge Biopharma Plc operates as a commercial-stage biopharmaceutical company, which focuses on the development and commercialization of therapies for rare diseases. Its pipeline is comprised of Keveyis, Macrilen, Recorlev, and Veldoreotide. The company was founded on May 26, 2015 and is headquartered in Trevose, PA.